{"id":336642,"date":"2020-03-08T12:47:31","date_gmt":"2020-03-08T09:47:31","guid":{"rendered":"https:\/\/kinsta.unitedwithisrael.org\/?p=336642"},"modified":"2020-03-08T13:20:25","modified_gmt":"2020-03-08T10:20:25","slug":"medecine-une-technologie-israelienne-permet-de-determiner-le-traitement-adapte-au-cancer-du-sein-en-seulement-72-heures","status":"publish","type":"post","link":"https:\/\/kinsta.unitedwithisrael.org\/fr\/medecine-une-technologie-israelienne-permet-de-determiner-le-traitement-adapte-au-cancer-du-sein-en-seulement-72-heures\/","title":{"rendered":"M\u00e9decine: Une technologie isra\u00e9lienne permet de d\u00e9terminer le traitement adapt\u00e9 au cancer du sein en seulement 72 heures!"},"content":{"rendered":"

Une start-up isra\u00e9lienne d\u00e9veloppe une m\u00e9thode pour r\u00e9duire consid\u00e9rablement le temps n\u00e9cessaire pour administrer un traitement efficace.<\/strong><\/em><\/p>\n

Par TPS<\/em><\/p>\n

Les experts de Barcode Diagnostics, une soci\u00e9t\u00e9 fond\u00e9e \u00e0 l’Institut isra\u00e9lien du Technion, d\u00e9veloppent une technologie innovante pour r\u00e9duire le temps n\u00e9cessaire pour identifier le traitement optimal pour les patients canc\u00e9reux, r\u00e9duisant ainsi le temps n\u00e9cessaire de plusieurs mois \u00e0 seulement 72 heures.<\/p>\n

Le PDG de Barcode, Ronen Eavri, a expliqu\u00e9 \u00e0 TPS la technologie derri\u00e8re son produit et comment elle permettait de fournir aux m\u00e9decins le bon outil n\u00e9cessaire pour lutter efficacement contre le cancer.<\/p>\n

L’id\u00e9e est simple: lorsqu’une personne re\u00e7oit un diagnostic de cancer du sein triple n\u00e9gatif, un m\u00e9decin a le choix entre plusieurs formes de m\u00e9dicaments pour lutter contre le cancer. Chaque patient r\u00e9agit diff\u00e9remment aux m\u00e9dicaments; ce qui donne des effets positifs \u00e0 un patient peut n’avoir aucun effet sur un autre.<\/p>\n

Actuellement, les m\u00e9decins testent chaque m\u00e9dicament pendant trois mois, apr\u00e8s quoi ils passent au suivant si aucun r\u00e9sultat b\u00e9n\u00e9fique n’est d\u00e9montr\u00e9.<\/p>\n

C’est l\u00e0 que Barcode Diagnostics entre en jeu: la start-up propose une \u00abm\u00e9thode de d\u00e9pistage bas\u00e9e sur les nanotechnologies<\/em>\u00bb, a d\u00e9clar\u00e9 Eavri \u00e0 TPS, qui r\u00e9duit le temps n\u00e9cessaire pour d\u00e9terminer le m\u00e9dicament optimal d’un minimum de trois mois \u00e0 seulement 72 heures.<\/p>\n

Au lieu de tester des m\u00e9dicaments individuellement et sur une longue p\u00e9riode, Barcode Diagnostics envoie simultan\u00e9ment diff\u00e9rents m\u00e9dicaments au syst\u00e8me sanguin en \u00abencapsulant des m\u00e9dicaments dans des nanoparticules et en les pla\u00e7ant avec des codes-barres mol\u00e9culaires. De cette fa\u00e7on, nous pouvons g\u00e9n\u00e9rer diff\u00e9rentes nanoparticules qui se ressemblent \u00e0 l’ext\u00e9rieur mais avec une cargaison diff\u00e9rente<\/em> \u00bb, permettant \u00e0 Eavri et \u00e0 son \u00e9quipe de mesurer l’efficacit\u00e9 de chaque m\u00e9dicament sur la tumeur canc\u00e9reuse.<\/p>\n

La technologie r\u00e9volutionnaire injecte simultan\u00e9ment toutes les nanoparticules pertinentes avec des codes-barres dans la circulation sanguine du patient en tr\u00e8s petites quantit\u00e9s o\u00f9 elles atteignent la tumeur.<\/p>\n

\u00abSi un m\u00e9dicament est puissant, il tuera cette cellule. 48 heures apr\u00e8s l’injection, le m\u00e9decin pr\u00e9l\u00e8ve une biopsie sur la tumeur. La biopsie pr\u00e9sente des cellules mortes et des cellules vivantes que nous s\u00e9parons. Si un m\u00e9dicament est puissant, une plus grande partie de son code-barres ira dans les cellules mortes<\/em> \u00bb, explique l’Universit\u00e9 h\u00e9bra\u00efque et le MIT Eavri, expliquant comment une injection peut fournir aux m\u00e9decins les informations n\u00e9cessaires pour d\u00e9terminer quel m\u00e9dicament utiliser dans le traitement \u00e0 long terme d’un patient.<\/p>\n

La soci\u00e9t\u00e9 isra\u00e9lienne quantifie ensuite le nombre de codes-barres trouv\u00e9s dans les cellules canc\u00e9reuses mortes, ce qui lui permet de d\u00e9terminer l’efficacit\u00e9 des m\u00e9dicaments individuels test\u00e9s.<\/p>\n

\u00abPlus il y a de codes-barres d’un m\u00e9dicament dans les cellules mortes, plus le m\u00e9dicament est efficace<\/em>\u00bb, a expliqu\u00e9 le PDG, soulignant comment sa m\u00e9thode de d\u00e9termination du m\u00e9dicament qui convient \u00e0 un patient peut aider les m\u00e9decins \u00e0 commencer un traitement efficace contre le cancer plusieurs mois plus t\u00f4t que ce n’est actuellement le cas. : \u00ab48 heures \u00e0 l’int\u00e9rieur du patient, 24 heures pour notre analyse. Au total, 72 heures est le temps qu’il nous faut pour fournir un rapport au m\u00e9decin sur l’activit\u00e9 des diff\u00e9rents m\u00e9dicaments chez un patient. Nous pouvons r\u00e9duire consid\u00e9rablement le temps actuellement n\u00e9cessaire.<\/em> \u00bb<\/p>\n

Barcode Diagnostics concentre ses recherches actuelles sur le cancer du sein, mais voit son id\u00e9e comme \u00abune plate-forme technologique [pas seulement pour le cancer du sein]<\/em>\u00bb.<\/p>\n

Eavri a ajout\u00e9 que \u00aben tant que startup, nous sommes tr\u00e8s concentr\u00e9s sur la fourniture d’une preuve de concept, nous nous concentrons sur le cancer du sein triple n\u00e9gatif<\/em>\u00bb.<\/p>\n

Une fois que cette preuve de concept est l\u00e0, la startup s’engage \u00e0 s’\u00e9tendre \u00e0 d’autres types de cancer.<\/p>\n

\u00abNous devons encore prouver que cela fonctionne chez l’humain et c’est pourquoi nous pr\u00e9parons la premi\u00e8re \u00e9tude chez l’homme [en Isra\u00ebl]<\/em>\u00bb, a d\u00e9clar\u00e9 Eavri, ajoutant que \u00abc’est une innovation r\u00e9volutionnaire. Si cela fonctionne, ce sera une perc\u00e9e incroyable pour s\u00e9lectionner le traitement optimal et pour aider les m\u00e9decins \u00e0 d\u00e9cider quels m\u00e9dicaments [utiliser] pour traiter le cancer du sein triple n\u00e9gatif en premier, et d’autres indications de cancer \u00e0 l’avenir<\/em>.\u00a0\u00bb<\/p>\n

Do You Love Israel? Make a Donation - Show Your Support!<\/h2>
\"\"<\/a>

<\/p><\/div>

Donate to vital charities<\/strong><\/a> that help protect Israeli citizens and inspire millions around the world to support Israel too! <\/p>

Now more than ever, Israel needs your help to fight and win the war -- including on the battlefield of public opinion. <\/p>

Antisemitism, anti-Israel bias and boycotts are out of control. Israel's enemies are inciting terror and violence against innocent Israelis and Jews around the world. Help us fight back!<\/strong><\/a> <\/p>

STAND WTH ISRAEL - MAKE A DONATION TODAY!<\/a><\/strong><\/p><\/div><\/shortcode>

\"Donate<\/a><\/div><\/ad-shortcode><\/non-auwi>","protected":false},"excerpt":{"rendered":"

Une start-up isra\u00e9lienne d\u00e9veloppe une m\u00e9thode pour r\u00e9duire consid\u00e9rablement le temps n\u00e9cessaire pour administrer un traitement efficace. Par TPS Les experts de Barcode Diagnostics, une soci\u00e9t\u00e9 fond\u00e9e \u00e0 l’Institut isra\u00e9lien du Technion, d\u00e9veloppent une technologie innovante pour r\u00e9duire le temps n\u00e9cessaire pour identifier le traitement optimal pour les patients canc\u00e9reux, r\u00e9duisant ainsi le temps n\u00e9cessaire… Read more »<\/a><\/p>\n","protected":false},"author":4242,"featured_media":266266,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[28418],"tags":[33896,34248,29798,29313,29783,28846],"class_list":["post-336642","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-actualites-israeliennes","tag-cancer-fr","tag-innovation-fr","tag-medecine","tag-recherche","tag-sante","tag-traitement"],"better_featured_image":{"id":266266,"alt_text":"Cancer immunotherapy research","caption":"Cancer immunotherapy research with cell and test tube. (Shutterstock)","description":"Cancer immunotherapy research with cell and test tube. (Shutterstock)","media_type":"image","media_details":{"width":1000,"height":667,"file":"2018\/02\/shutterstock_578121211.jpg","sizes":{"thumbnail":{"file":"shutterstock_578121211-150x150.jpg","width":150,"height":150,"mime-type":"image\/jpeg","source_url":"https:\/\/kinsta.unitedwithisrael.org\/wp-content\/uploads\/2018\/02\/shutterstock_578121211-150x150.jpg"},"medium":{"file":"shutterstock_578121211-300x200.jpg","width":300,"height":200,"mime-type":"image\/jpeg","source_url":"https:\/\/kinsta.unitedwithisrael.org\/wp-content\/uploads\/2018\/02\/shutterstock_578121211-300x200.jpg"},"medium_large":{"file":"shutterstock_578121211-768x512.jpg","width":768,"height":512,"mime-type":"image\/jpeg","source_url":"https:\/\/kinsta.unitedwithisrael.org\/wp-content\/uploads\/2018\/02\/shutterstock_578121211-768x512.jpg"},"uwi-full-width":{"file":"shutterstock_578121211-780x520.jpg","width":780,"height":520,"mime-type":"image\/jpeg","source_url":"https:\/\/kinsta.unitedwithisrael.org\/wp-content\/uploads\/2018\/02\/shutterstock_578121211-780x520.jpg"},"uwi-featured-carousel":{"file":"shutterstock_578121211-890x400.jpg","width":890,"height":400,"mime-type":"image\/jpeg","source_url":"https:\/\/kinsta.unitedwithisrael.org\/wp-content\/uploads\/2018\/02\/shutterstock_578121211-890x400.jpg"},"uwi-featured-content":{"file":"shutterstock_578121211-290x160.jpg","width":290,"height":160,"mime-type":"image\/jpeg","source_url":"https:\/\/kinsta.unitedwithisrael.org\/wp-content\/uploads\/2018\/02\/shutterstock_578121211-290x160.jpg"},"uwi-content-loop":{"file":"shutterstock_578121211-190x190.jpg","width":190,"height":190,"mime-type":"image\/jpeg","source_url":"https:\/\/kinsta.unitedwithisrael.org\/wp-content\/uploads\/2018\/02\/shutterstock_578121211-190x190.jpg"},"uwi-category_list":{"file":"shutterstock_578121211-180x100.jpg","width":180,"height":100,"mime-type":"image\/jpeg","source_url":"https:\/\/kinsta.unitedwithisrael.org\/wp-content\/uploads\/2018\/02\/shutterstock_578121211-180x100.jpg"},"uwi-tiny":{"file":"shutterstock_578121211-40x40.jpg","width":40,"height":40,"mime-type":"image\/jpeg","source_url":"https:\/\/kinsta.unitedwithisrael.org\/wp-content\/uploads\/2018\/02\/shutterstock_578121211-40x40.jpg"},"uwi-email-featured":{"file":"shutterstock_578121211-250x170.jpg","width":250,"height":170,"mime-type":"image\/jpeg","source_url":"https:\/\/kinsta.unitedwithisrael.org\/wp-content\/uploads\/2018\/02\/shutterstock_578121211-250x170.jpg"},"uwi-email":{"file":"shutterstock_578121211-200x140.jpg","width":200,"height":140,"mime-type":"image\/jpeg","source_url":"https:\/\/kinsta.unitedwithisrael.org\/wp-content\/uploads\/2018\/02\/shutterstock_578121211-200x140.jpg"},"uwi-iphone":{"file":"shutterstock_578121211-960x640.jpg","width":960,"height":640,"mime-type":"image\/jpeg","source_url":"https:\/\/kinsta.unitedwithisrael.org\/wp-content\/uploads\/2018\/02\/shutterstock_578121211-960x640.jpg"},"uwi-iphone-x2":{"file":"shutterstock_578121211-1000x640.jpg","width":1000,"height":640,"mime-type":"image\/jpeg","source_url":"https:\/\/kinsta.unitedwithisrael.org\/wp-content\/uploads\/2018\/02\/shutterstock_578121211-1000x640.jpg"},"uwi-full-width-video":{"file":"shutterstock_578121211-779x519.jpg","width":779,"height":519,"mime-type":"image\/jpeg","source_url":"https:\/\/kinsta.unitedwithisrael.org\/wp-content\/uploads\/2018\/02\/shutterstock_578121211-779x519.jpg"},"uwi-fb-share-video":{"file":"shutterstock_578121211-600x315.jpg","width":600,"height":315,"mime-type":"image\/jpeg","source_url":"https:\/\/kinsta.unitedwithisrael.org\/wp-content\/uploads\/2018\/02\/shutterstock_578121211-600x315.jpg"},"uwi-fb-share":{"file":"shutterstock_578121211-600x320.jpg","width":600,"height":320,"mime-type":"image\/jpeg","source_url":"https:\/\/kinsta.unitedwithisrael.org\/wp-content\/uploads\/2018\/02\/shutterstock_578121211-600x320.jpg"},"uwi-featured-content-video":{"file":"shutterstock_578121211-289x159.jpg","width":289,"height":159,"mime-type":"image\/jpeg","source_url":"https:\/\/kinsta.unitedwithisrael.org\/wp-content\/uploads\/2018\/02\/shutterstock_578121211-289x159.jpg"},"uwi-content-loop-video":{"file":"shutterstock_578121211-189x189.jpg","width":189,"height":189,"mime-type":"image\/jpeg","source_url":"https:\/\/kinsta.unitedwithisrael.org\/wp-content\/uploads\/2018\/02\/shutterstock_578121211-189x189.jpg"},"uwi-category_list-video":{"file":"shutterstock_578121211-179x99.jpg","width":179,"height":99,"mime-type":"image\/jpeg","source_url":"https:\/\/kinsta.unitedwithisrael.org\/wp-content\/uploads\/2018\/02\/shutterstock_578121211-179x99.jpg"},"uwi-tiny-video":{"file":"shutterstock_578121211-39x39.jpg","width":39,"height":39,"mime-type":"image\/jpeg","source_url":"https:\/\/kinsta.unitedwithisrael.org\/wp-content\/uploads\/2018\/02\/shutterstock_578121211-39x39.jpg"},"uwi-email-featured-video":{"file":"shutterstock_578121211-249x169.jpg","width":249,"height":169,"mime-type":"image\/jpeg","source_url":"https:\/\/kinsta.unitedwithisrael.org\/wp-content\/uploads\/2018\/02\/shutterstock_578121211-249x169.jpg"},"uwi-email-video":{"file":"shutterstock_578121211-209x139.jpg","width":209,"height":139,"mime-type":"image\/jpeg","source_url":"https:\/\/kinsta.unitedwithisrael.org\/wp-content\/uploads\/2018\/02\/shutterstock_578121211-209x139.jpg"},"uwi-iphone-video":{"file":"shutterstock_578121211-959x639.jpg","width":959,"height":639,"mime-type":"image\/jpeg","source_url":"https:\/\/kinsta.unitedwithisrael.org\/wp-content\/uploads\/2018\/02\/shutterstock_578121211-959x639.jpg"},"uwi-iphone-x2-video":{"file":"shutterstock_578121211-1000x639.jpg","width":1000,"height":639,"mime-type":"image\/jpeg","source_url":"https:\/\/kinsta.unitedwithisrael.org\/wp-content\/uploads\/2018\/02\/shutterstock_578121211-1000x639.jpg"},"post-thumbnail":{"file":"shutterstock_578121211-125x125.jpg","width":125,"height":125,"mime-type":"image\/jpeg","source_url":"https:\/\/kinsta.unitedwithisrael.org\/wp-content\/uploads\/2018\/02\/shutterstock_578121211-125x125.jpg"}},"image_meta":{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"0","keywords":[]}},"post":null,"source_url":"https:\/\/kinsta.unitedwithisrael.org\/wp-content\/uploads\/2018\/02\/shutterstock_578121211.jpg"},"aioseo_notices":[],"distributor_meta":false,"distributor_terms":false,"distributor_media":false,"distributor_original_site_name":"Unis avec Isra\u00ebl","distributor_original_site_url":"https:\/\/kinsta.unitedwithisrael.org\/fr\/","push-errors":false,"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/kinsta.unitedwithisrael.org\/fr\/wp-json\/wp\/v2\/posts\/336642","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kinsta.unitedwithisrael.org\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kinsta.unitedwithisrael.org\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kinsta.unitedwithisrael.org\/fr\/wp-json\/wp\/v2\/users\/4242"}],"replies":[{"embeddable":true,"href":"https:\/\/kinsta.unitedwithisrael.org\/fr\/wp-json\/wp\/v2\/comments?post=336642"}],"version-history":[{"count":0,"href":"https:\/\/kinsta.unitedwithisrael.org\/fr\/wp-json\/wp\/v2\/posts\/336642\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/kinsta.unitedwithisrael.org\/fr\/wp-json\/wp\/v2\/media\/266266"}],"wp:attachment":[{"href":"https:\/\/kinsta.unitedwithisrael.org\/fr\/wp-json\/wp\/v2\/media?parent=336642"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kinsta.unitedwithisrael.org\/fr\/wp-json\/wp\/v2\/categories?post=336642"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kinsta.unitedwithisrael.org\/fr\/wp-json\/wp\/v2\/tags?post=336642"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}